Iovance Biotherapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Iovance Biotherapeutics has a total shareholder equity of $584.6M and total debt of $1,000.0K, which brings its debt-to-equity ratio to 0.2%. Its total assets and total liabilities are $780.4M and $195.7M respectively.
Key information
0.2%
Debt to equity ratio
US$1.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$279.87m |
| Equity | US$584.61m |
| Total liabilities | US$195.74m |
| Total assets | US$780.35m |
Recent financial health updates
Recent updates
Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Mar 25Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Feb 20Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Jan 19Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates
Sep 27Iovance submits rolling license application to FDA for skin cancer treatment lifileucel
Aug 25Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Aug 25
Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss
Aug 04Iovance: TIL Cell Therapy Set To Prove Itself
Jul 11Iovance: Onward To Approval
Apr 20Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside
Mar 25Iovance Biotherapeutics: Uncertainty And Opportunity
Dec 05Iovanve Biotherapeutics (IOVA) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow
Jun 16Iovance Bio reports 33-month follow up data for lifileucel in advanced melanoma at ASCO21
Jun 07Iovance: Down And Rebound
May 30Here's Why We're Not Too Worried About Iovance Biotherapeutics' (NASDAQ:IOVA) Cash Burn Situation
Mar 16Financial Position Analysis
Short Term Liabilities: IOVA's short term assets ($307.8M) exceed its short term liabilities ($110.3M).
Long Term Liabilities: IOVA's short term assets ($307.8M) exceed its long term liabilities ($85.4M).
Debt to Equity History and Analysis
Debt Level: IOVA has more cash than its total debt.
Reducing Debt: IOVA's debt to equity ratio has increased from 0% to 0.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IOVA has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: IOVA has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 23.8% each year.